12 January 2021 - Independent UK (MHRA) application to run in parallel with ongoing European (EMA) application, following end of Brexit Transition period.

Diurnal Group announces that an ‘in flight’ Market Authorisation Application (MAA) has been submitted to the UK Medicines and Healthcare products Regulatory Agency (MHRA) for Chronocort (modified-release hydrocortisone) as a treatment for adult and adolescent patients with the rare condition congenital adrenal hyperplasia in Great Britain (England, Wales and Scotland).

Read Diurnal press release